Berenice Román

Ms. Berenice Román

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2025 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
BPBryan A. Priego-Parra
Bryan A. Priego-Parra
RGRocio Gallego-Duran
Rocio Gallego-Duran
BRBerenice Román
Berenice Román
JVJose Antonio Velarde-Ruiz Velasco
Jose Antonio Velarde-Ruiz Velasco
MRManuel Romero-Gómez
Manuel Romero-Gómez
Jordi Gracia-SanchoJordi Gracia-Sancho
Jordi Gracia-Sancho

14 April 2023 in JHEP Reports
Verified
Journal Article
Open access
ARAstrid Ruiz-Margáin
Astrid Ruiz-Margáin
APAlessandra Pohlmann
Alessandra Pohlmann
SLSilke Lanzerath
Silke Lanzerath
MLMelanie Langheinrich
Melanie Langheinrich
ACAlejandro Campos-Murguía
Alejandro Campos-Murguía
JTJonel Trebicka
Jonel Trebicka
Acute-on-chronic liver failure (ACLF) has been linked to different pathophysiological mechanisms, including systemic inflammation and mitochondrial dysfunction. Sarcopenia has also been proposed as a potential mechanism; myostatin is a key factor inducing sarcopenia. Therefore, this study aimed to evaluate the association of myostatin levels with the development of ACLF and mortality in patients with cirrhosis. We performed a prospective cohort study, including both outpatient and hospitalized patients with cirrhosis. Clinical, biochemical, and nutritional parameters were evaluated, and the development of acute decompensation (AD) or ACLF during follow-up was recorded. ACLF was defined according to the EASL-CLIF criteria. Receiver-operating characteristic, Kaplan-Meier and Cox regression analyses were performed. A total of 186 patients with the whole spectrum of cirrhosis were included; mean age was 53.4 ± 14 years, mean Child-Pugh score was 8 ± 2.5 and mean MELD score was 15 ± 8. There was a stepwise decrease in myostatin levels from a compensated stage to AD and ACLF. Myostatin correlated positively with nutritional markers and negatively with severity scores. The prevalence of sarcopenia was 73.6%. During follow-up, 27.9% of patients developed AD and 25.8% developed ACLF. Most episodes were grade 2-3, mainly (62.5%) precipitated by infections. The most common organ failures observed were in the liver (63.3%) and the kidney (64.6%). Receiver-operating characteristic analysis yielded <1,280 pg/ml as the best serum myostatin cut-off for the prediction of ACLF. In Kaplan-Meier curves and multivariate analysis, myostatin levels remained independently associated with the incidence of ACLF and survival. There is a progressive decrease in myostatin levels as cirrhosis progresses, demonstrating an association of sarcopenia with the development of ACLF and increased mortality. Myostatin is a muscle hormone, it is decreased in patients with muscle loss and is a marker of impaired muscle function. In this study we show that myostatin levels are decreased in patients with cirrhosis, with lower levels in patients with acute decompensation and acute-on chronic liver failure (ACLF). Low myostatin levels in cirrhosis predict the development of ACLF and mortality independently of liver disease severity and sex.

6 August 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
MTMonica Sanchez Tapia
Monica Sanchez Tapia
STSandra Tobon-Cornejo
Sandra Tobon-Cornejo
LNLilia G. Noriega
Lilia G. Noriega
NVNatalia Vázquez
Natalia Vázquez
DCDiana Coutiño-Hernández
Diana Coutiño-Hernández
Nimbe TorresNimbe Torres
Nimbe Torres
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a serious health problem, and recent evidence indicates that gut microbiota plays a key role in its development. It is known that 2-oleoyl glycerol (2-OG) produced by the gut microbiota is associated with hepatic fibrosis, but it is not known whether this metabolite is involved in the development of hepatic steatosis. The aim of this study was to evaluate how a high-fat–sucrose diet (HFS) increases 2-OG production through gut microbiota dysbiosis and to identify whether this metabolite modifies hepatic lipogenesis and mitochondrial activity for the development of hepatic steatosis as well as whether a combination of functional foods can reverse this process. Wistar rats were fed the HFS diet for 7 months. At the end of the study, body composition, biochemical parameters, gut microbiota, protein abundance, lipogenic and antioxidant enzymes, hepatic 2-OG measurement, and mitochondrial function of the rats were evaluated. Also, the effect of the consumption of functional food with an HFS diet was assessed. In humans with MASLD, we analyzed gut microbiota and serum 2-OG. Consumption of the HFS diet in Wistar rats caused oxidative stress, hepatic steatosis, and gut microbiota dysbiosis, decreasing α-diversity and increased Blautia producta abundance, which increased 2-OG. This metabolite increased de novo lipogenesis through ChREBP and SREBP-1. 2-OG significantly increased mitochondrial dysfunction. The addition of functional foods to the diet modified the gut microbiota, reducing Blautia producta and 2-OG levels, leading to a decrease in body weight gain, body fat mass, serum glucose, insulin, cholesterol, triglycerides, fatty liver formation, and increased mitochondrial function. To use 2-OG as a biomarker, this metabolite was measured in healthy subjects or with MASLD, and it was observed that subjects with hepatic steatosis II and III had significantly higher 2-OG than healthy subjects, suggesting that the abundance of this circulating metabolite could be a predictor marker of hepatic steatosis.

10 July 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
MTMonica Sanchez Tapia
Monica Sanchez Tapia
STSandra Tobon-Cornejo
Sandra Tobon-Cornejo
LNLilia G. Noriega
Lilia G. Noriega
NVNatalia Vázquez
Natalia Vázquez
DCDiana Coutiño-Hernández
Diana Coutiño-Hernández
Nimbe TorresNimbe Torres
Nimbe Torres
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a serious health problem, and recent evidence indicates that gut microbiota plays a key role in its development. It is known that 2-oleoyl glycerol (2-OG) produced by the gut microbiota is associated with hepatic fibrosis, but it is not known whether this metabolite is involved in the development of hepatic steatosis. The aim of this study was to evaluate how a high-fat sucrose diet (HFS) increases 2-OG production through gut microbiota dysbiosis and to identify whether this metabolite modifies hepatic lipogenesis and mitochondrial activity for the development of hepatic steatosis as well as whether a combination of functional foods can reverse this process. Wistar rats were fed HFS diet for 7 mo. At the end of the study, body composition, biochemical parameters, gut microbiota, protein abundance of lipogenic and antioxidant enzymes, measurement of liver 2-OG, and mitochondrial function were assessed in rats and we studied the effect of HFS with functional foods. In humans with MASLD, we analyzed gut microbiota and serum 2-OG. Consumption of HFS diet in Wistar rats caused oxidative stress, hepatic steatosis and gut microbiota dysbiosis, decreasing α-diversity and increased Blautia producta abundance, which increased 2-OG. This metabolite increased de novo lipogenesis through ChREBP and SREBP-1. 2-OG significantly increased mitochondrial dysfunction. Addition of functional foods to the diet modified the gut microbiota, reducing B. producta and 2-OG levels, leading to a decrease in body weight gain, body fat mass, serum glucose, insulin, cholesterol, triglycerides, fatty liver formation, and increased mitochondrial function. In order to use 2-OG as biomarker, this metabolite was measured in healthy subjects or with MASLD and it was observed that subjects with hepatic steatosis II and III had significantly higher 2-OG than healthy subjects, suggesting that the abundance of this circulating metabolite could be a predictor marker of hepatic steatosis.

3 November 2025 in Liver Transplantation
Verified
Journal Article
Closed access
BRBerenice Román
Berenice Román
ARAstrid Ruiz-Margáin
Astrid Ruiz-Margáin
ADAndres Duarte-Rojo
Andres Duarte-Rojo
FFFernando Flores-Silva
Fernando Flores-Silva
CMCarlos Fernando Martinez-Cabrera
Carlos Fernando Martinez-Cabrera
RMRicardo Macías-Rodríguez
Ricardo Macías-Rodríguez
Physical exercise improves liver and body composition markers in metabolic dysfunction–associated fatty liver disease (MASLD), but its effects on cerebral hemodynamics and cognitive function in patients with MASLD remain unexplored. We aimed to evaluate the effect of a monitored 16-week exercise intervention on cerebral hemodynamics and cognitive function in patients with MASLD. In this randomized clinical trial, 40 obese patients with MASLD were randomized to either a control group (n=20) on a caloric restriction diet, or an intervention group (n=20) receiving diet plus exercise. The exercise intervention consisted of gradual increases in daily steps and resistance training. Both groups also received monthly classic literature readings to ensure comparable cognitive engagement throughout the study. Transcranial Doppler ultrasound and neurocognitive tests were assessed as primary outcomes. Secondary outcomes included body composition and liver disease parameters. Participants were 60% female, with a mean age of 47±8 years. Intervention adherence was >80%. Daily steps doubled in the intervention group (from 5178 to 10,161; p <0.001) with no changes in controls. The intervention group showed an 8.4% reduction in peripheral arterial stiffness ( p =0.002), 10.4% reduction in resistance index ( p <0.001), and 19.2% decrease in pulsatility index ( p <0.001) with no significant changes in controls. Cognitive function improved in the intervention group, with a 5.9% increase in MoCA score ( p =0.005) and 6.6% increase in Addenbrooke score ( p <0.001). Both groups showed a significant reduction in BMI and body fat percentage (−5.2% and 10.5% intervention, vs. −2.7% and 3.8% in controls). A structured, monitored exercise program improves cerebral hemodynamics, arterial stiffness, and cognitive function in patients with MASLD (NCT05520697).

29 July 2026 in Frontiers in Nutrition
Verified
Journal Article
Open access
PDF file
BRBerenice Román
Berenice Román
BPBryan Adrian Priego-Parra
Bryan Adrian Priego-Parra
CMCarlos Fernando Martínez-Cabrera
Carlos Fernando Martínez-Cabrera
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, affecting nearly one-third of the global population 1 . Lifestyle modification, including nutritional intervention, remains the cornerstone of MASLD management. Although weight loss of >7-10% is recommended to improve liver histology and metabolic outcomes, individual responses to dietary interventions vary considerably, reflecting the heterogeneous clinical, metabolic, and biological characteristics of the disease.Precision nutrition has emerged as a promising framework to address this heterogeneity by integrating lifestyle and behavioral factors, body composition, metabolic biomarkers, environmental exposures, cultural preferences, and genomic, molecular, and microbiome-related characteristics into individualized nutritional approaches 2 . As illustrated in Figure 1, precision nutrition in MASLD encompasses a continuum from multidimensional patient characterization and integrated patient assessment to the implementation of personalized dietary and lifestyle interventions aimed at improving both hepatic and extrahepatic outcomes.The articles assembled in this Research Topic illustrate how the principles of precision nutrition can be translated into practical strategies for the management of MASLD.The marked heterogeneity partly explains why uniform nutritional recommendations often produce variable responses in MASLD. Integrated patient assessment provides a framework to identify clinically meaningful sources of heterogeneity that may influence disease progression and response to dietary interventions. Metabolic and inflammatory phenotyping are key components of this multidimensional assessment. In this context, Ntikoudi emphasizes that clinically meaningful metabolic and inflammatory profiles can be identified using readily available biomarkers, such as HOMA-IR, TG/HDL-C, and hs-CRP, without necessarily relying on complex omics technologies.Along similar lines, Priego-Parra et al. 3 highlighted the triglyceride-glucose-waist circumference (TyG-WC) index as a practical surrogate of insulin resistance, visceral adiposity, and cardiometabolic risk, illustrating how accessible metabolic biomarkers can guide personalized nutritional management in MASLD. These advances reinforce the growing role of simple metabolic and nutritional biomarkers in refining patient assessment and guiding precision nutrition.Accessible metabolic and nutritional biomarkers are emerging as key tools for refining integrated patient assessment and improving risk stratification in MASLD. In Beyond its role as a relevant therapeutic intervention, diet has been recognized as a significant contributor to the development of MASLD and a major modifiable risk factor. In this context, Qiu et al. showed that greater to the Planetary Health Diet Index (PHDI) was associated with a lower likelihood of MASLD, with the effect partly mediated by body mass index and waist circumference. In addition, Yang et al. demonstrated that greater adherence to the MIND Diet Score was associated with improved hepatic and metabolic health together with a more favorable gut microbiota profile, supporting the potential role of comprehensive dietary quality indices in precision nutrition. Siani et al. further reported an inverse, dose-dependent association between Italian-style coffee consumption and MASLD risk, with lower odds observed as daily coffee intake increased. Although this observational study does not establish causality, it highlights the potential relevance of specific dietary exposures in modulating MASLD risk. Taken together, these studies reinforce the importance of dietary quality and selected nutritional exposures in MASLD and support the inclusion of both overall dietary patterns and individual dietary components in nutritional assessment.Dietary interventions, reduced intake of sugar-sweetened beverages (Li et al), and regular physical activity improve metabolic health and body composition while modulating key pathways involved in disease progression, including insulin resistance, systemic inflammation, and gut microbial ecology. Growing evidence positions the gut microbiota as a key mediator linking environmental exposures with hepatic and metabolic dysfunction. Within this framework, diet should be considered not only as a source of nutrients but also as a therapeutic modulator of hostmicrobiome interactions. Bioactive components, including omega-3 fatty acids, coffee, tea, and fermented foods, have been associated with favorable metabolic and microbial profiles, although their molecular mechanisms remain incompletely understood.These effects are closely related to the gut-liver axis, through which microbial metabolites and microbial-associated molecular patterns influence hepatic homeostasis. During dysbiosis, increased exposure to lipopolysaccharides, altered bile acid metabolism, and other microbial products may promote adipose tissue dysfunction, oxidative stress, mitochondrial impairment, and chronic inflammation, thereby supporting dietary and microbiota-targeted approaches as therapeutic Collectively, these advances support a shift from a liver-centered view of MASLD toward a systems-based framework integrating host metabolism, immunity, and the intestinal microbiome. This perspective aligns with the concept of the human holobiont and may facilitate the development of more precise and biologically informed therapeutic strategies.Lifestyle modification remains the cornerstone of MASLD management, with dietary intervention and increased physical activity representing the foundation of current therapeutic strategies. However, substantial interindividual variability in treatment response highlights the limitations of a uniform approach. Integrating precision nutrition into clinical care offers an opportunity to tailor dietary interventions according to each patient's metabolic phenotype, body...